about
2016 updated EULAR evidence-based recommendations for the management of gout.A review of uric acid, crystal deposition disease, and gout.Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsCellular adhesion gene SELP is associated with rheumatoid arthritis and displays differential allelic expression.Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.EULAR recommendations for calcium pyrophosphate deposition. Part II: management.Usefulness of ultrasonography for gout.Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional surveyHow to define responders in osteoarthritis.Efficacy of anakinra in gouty arthritis: a retrospective study of 40 casesInternational position paper on febuxostat.European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.Needle aponeurotomy in Dupuytren's disease.Gout: why is this curable disease so seldom cured?How to manage patients with gout.Definition of hyperuricemia and gouty conditions.Prophylaxis for acute gout flares after initiation of urate-lowering therapy.Pharmacokinetics considerations for gout treatments.Improving cardiovascular and renal outcomes in gout: what should we target?Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout.Assessment of dynamic humeral centering in shoulder pain with impingement syndrome: a randomised clinical trial.Serum uric acid and the risk of cardiovascular and renal disease.Dyslipidemia, Alcohol Consumption and Obesity are the Main Factors Associated with Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence.Treat-to-target (T2T) recommendations for gout.Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.Multi-needle aponeurotomy for advanced Dupuytren's disease: preliminary results of safety and efficacy (MNA 1 study).Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study.Gout: An old disease in new perspective - A review.Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis.Prevalence of Gout in the Adult Population of France.Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.Multiple Giant Cell Tumors of the Tendon Sheath : Separate Volar and Dorsal Lesions Involving Three Digits of the Same Hand Following Repetitive Trauma.
P50
Q30248787-E1250E31-F425-4FA3-808A-B2ADFEC60167Q30619265-756941E7-BF58-461B-A43D-CA488811E605Q33864537-C72EADE4-1B73-4A28-BBB3-D5E01BBBB4A6Q34078388-7EB16B59-62F8-4175-8D88-4912E293DB7AQ34276905-930947F9-03CD-4375-901C-C0635E837B3DQ34626526-5DE2AE9B-377B-4C0E-B5AB-1F05B5B8AC68Q34636383-71E13AF2-5D5E-4132-AF9F-36D9148114E1Q36402266-7B57AA25-88F9-4C17-ABEF-390C0FA81EDAQ36949072-87060CA7-48F8-431B-8B30-D39C33B08BFAQ37690784-EF38C157-FFAE-417C-8069-E6FEC91139A5Q37733344-F10DB08D-4754-465F-8AB2-600BC38FA0CDQ37827003-C51E7861-ACB5-495C-ADDE-34CE6B5751D9Q37872929-08BCD3C1-1149-4650-9F8E-5EACF1DEA681Q38032068-CD76171A-C481-4367-94F3-ABF8A14F113EQ38102024-790845D2-E29D-4411-9ACA-B94820A783C9Q38178110-662B2C70-F965-4013-8B4E-80C579C1C383Q38206603-15C6D6DB-FB5D-46C7-AD29-2A250DF9586FQ38210284-132A3A96-F5A4-431C-B4F0-91B5181740B0Q38241233-771C23E7-50FC-4168-9CBE-271F3633C2C6Q38320887-85B906A8-2EAA-493A-AB14-33CA6640D9A4Q38490338-4934853A-C30B-4337-BB3D-AAC05F110A22Q38542013-E892442E-A727-4A4C-BAD3-930C3E3EA4B5Q38611676-5100EF25-CB3C-4C2C-91C1-3E4B2352B4B2Q38644685-BA68DB02-A5A6-4016-B7F6-660E52D0C7D3Q38683130-311C43DE-926F-4D76-AA81-DABBCD99C025Q38961824-265D9253-C598-47B9-9F1B-20A4FFE28113Q39203950-5D74175E-A6EF-46BB-8BAD-CBA556DCB928Q39207518-C16E95F4-B772-4FD4-8889-E990EEEF1B50Q39246960-4F5D535C-790D-4791-8898-D6F397CAABD4Q39807938-A282556E-6371-4937-8461-53A8EB003E03Q39972720-E51DDB1F-E404-4655-B943-4F5F17547E88Q40047193-3FC7C1E1-3BE2-4EEA-A1FB-BBEB357F1218Q40103417-1BF33E47-AAEA-47F3-BA51-211914E7A1F0Q40106739-EAAB72C8-6106-4045-8245-6D38153DA7CCQ40166507-6CAC7ACC-CB29-4830-8A49-C3882C9343F8Q40864639-6392B827-C612-4A7C-8774-5E9C7CB4D667Q41009303-8F23E14C-9765-42A9-8F71-2D58E0199CCAQ41521920-6DD7DB17-7D19-46C0-93EA-6F333909F5CCQ41709276-A50CEE79-CB85-4122-BD45-EFEA88503D50Q41832463-5DE37CDD-A4E0-4219-81FF-5587373725AA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Bardin
@ast
Thomas Bardin
@en
Thomas Bardin
@es
Thomas Bardin
@nl
Thomas Bardin
@sl
type
label
Thomas Bardin
@ast
Thomas Bardin
@en
Thomas Bardin
@es
Thomas Bardin
@nl
Thomas Bardin
@sl
prefLabel
Thomas Bardin
@ast
Thomas Bardin
@en
Thomas Bardin
@es
Thomas Bardin
@nl
Thomas Bardin
@sl
P106
P21
P31
P496
0000-0002-5080-4790